With the CMS final rate announcement for 2027 expected in early April 2026, how will the finalized benchmark updates and risk adjustment changes impact Humana's (HUM) ability to achieve its stated multi-year Medicare Advantage margin recovery targets?

Executive Overview: Context & Scope As of March 31, 2026, the managed care sector is awaiting the Centers for Medicare & Medicaid Services (CMS) final Calendar Year 2027 Rate Announcement, expected in early April. The preliminary CY 2027 Advance Notice, released in late January 2026, proposed a net average year-over-year payment increase of just 0.09% , or 2.54% when factoring in estimated risk score trends. This analysis evaluates how these finalized benchmark updates and ongoing risk adjustment changes may impact Humana Inc.'s (HUM) stated multi-year Medicare Advantage (MA) margin recovery targets, particularly as the company navigates a structurally tighter federal funding environment. CMS 2027 Benchmark Updates: The "New Normal" Funding Environment The proposed 0.09% base rate increase represents a highly constrained funding environment for MA operators. When adjusted for current medical cost inflation—driven by elevated post-pandemic utilization of outpatient services, hospital admissions, and high-cost GLP-1 therapeutics—this update effectively functions as a real-dollar contraction. For Humana, which reported a 2025 adjusted EPS of $17.14 , adapting to this environment requires significant operational recalibration. If the final April rate mirrors the Advance Notice, MA plans will face a funding deficit relative to medical trend. This dynamic forces insurers to either absorb the costs (compressing margins) or aggressively reduce supplemental benefits to protect profitability. Impact on Humana's Multi-Year Margin Recovery Targets Humana’s management has previously outlined a multi-year target to double pre-tax MA margins (excluding the impact of Star Ratings) through tactical cost-cutting, supplier consolidation, and clinical efficiency. The 2027 rate environment introduces several friction points to this recovery trajectory: The Star Ratings Overhang: Humana is currently navigating a massive $3.5B Star Ratings headwind in 2026, a result of only 25% of its members residing in 4-star or higher plans. Margin recovery in 2027 is highly contingent on Humana’s ability to improve these scores during the measurement year to recapture quality bonus payments. A flat 2027 benchmark provides no organic revenue cushion to offset any lingering Star Rating deficits. Growth vs. Margin Trade-off: Humana recently experienced rapid individual MA membership growth, adding approximately 1,000,000 net members. However, management has signaled a strategic pivot toward prioritizing "stable and compelling margins" over volume. The tight 2027 rates will likely compel Humana to decommission unprofitable plans, exit certain geographic markets, and reduce benefit generosity, which could intentionally stall membership growth to protect the bottom line. Operating Leverage: To achieve its margin targets in a low-reimbursement environment, Humana must rely heavily on its internal transformation efforts. This includes expanding outsourcing capabilities, standardizing processes, and leveraging automation to drive down the operating expense ratio and offset top-line pressures. Risk Adjustment & Methodological Dynamics CMS continues to refine its risk adjustment models to curb coding intensity and ensure payment accuracy, guided by principles of simplicity and program integrity. These technical changes directly impact Humana's revenue yields: Unlinked Chart Reviews: The 2027 Advance Notice proposed excluding diagnoses submitted from chart reviews with unlinked claim records. CMS estimates this specific methodological change will reduce Part C payments by -1.53% . v28 Model Phase-In: The ongoing transition to the v28 risk adjustment model recalibrates hierarchical condition category (HCC) weights and removes certain diagnosis codes. For a mature, highly penetrated MA operator like Humana, these changes structurally pressure risk-adjusted revenue, requiring the company to rely more on core clinical management rather than coding optimization to maintain margins. Key Risks, Limitations, & Uncertainties Final Rate Variance: Historically, heavy industry lobbying can result in a final April rate that is slightly more favorable than the Advance Notice. However, given the current regulatory focus on fiscal responsibility, a material upward revision appears unlikely. Medical Loss Ratio (MLR) Volatility: If senior utilization of hospital services and expensive therapeutics spikes unexpectedly in 2026 or 2027, the constrained benchmark rates provide zero margin of error, risking further MLR deterioration. Execution Risk: Humana's ability to achieve its margin recovery is heavily dependent on internal execution—specifically, regaining its 4-star status and successfully implementing its cost-efficiency programs without degrading the member experience or retention rates.

Following the conclusion of the 2026 Medicare Advantage enrollment cycle, how should investors assess the impact of Humana's (HUM) 'value-over-volume' membership strategy on its projected 2026 earnings per share (EPS) and its long-term market share stability relative to diversified peers.

Executive Overview & Context Following the conclusion of the 2026 Medicare Advantage (MA) Annual Enrollment Period (AEP), Humana (HUM) is navigating a highly complex strategic inflection point. Historically reliant on aggressive market share expansion, the company initiated a "value-over-volume" margin repair strategy in 2025—intentionally shedding approximately 425,000 unprofitable individual MA members to target a sustainable 3.0% pre-tax margin. However, the 2026 enrollment cycle introduced a strategic paradox. While diversified peers contracted benefits and exited counties to protect margins against rising medical costs, Humana maintained or expanded certain plan benefits. This contrarian positioning resulted in a projected 25% surge in 2026 individual MA membership. For investors, assessing Humana requires reconciling this sudden volume influx with the severe earnings compression caused by the 2026 Star Ratings cliff and persistent medical cost inflation. Impact on Projected 2026 Earnings (EPS) Humana’s 2026 earnings profile is heavily distorted by regulatory headwinds, which temporarily mask underlying operational adjustments. The Star Ratings Cliff & EPS Compression: The primary driver of Humana's 2026 financial reset is the loss of CMS quality bonus payments. Management has introduced a baseline 2026 Adjusted EPS guidance of at least $9.00 (and GAAP EPS of at least $8.89 ). This represents a severe contraction from the 2025 Adjusted EPS guidance of $17.00 . The decline is explicitly attributed to the Star Ratings headwind for Bonus Year 2026, net of internal mitigation efforts. The Margin vs. Volume Paradox: The unexpected 25% growth in 2026 MA membership introduces significant near-term Medical Loss Ratio (MLR) risk. New MA cohorts typically run at higher initial loss ratios due to onboarding utilization and undocumented patient acuity. If this influx of new members utilizes care at the higher-end of mid-single-digit inflation trends, Humana’s Q3 2025 MLR baseline of 91.1% could face upward pressure, threatening the 3.0% pre-tax margin target. Pricing Adequacy: Management asserts that 2026 bids were priced to absorb these members profitably. However, the market remains cautious about whether Humana is repeating past missteps of capturing volume at the expense of unit economics. Long-Term Market Share Stability vs. Diversified Peers Humana’s structural positioning differs fundamentally from its primary competitors—UnitedHealth Group (UNH), Elevance Health (ELV), and CVS Health (CVS)—which rely on diversified profit pools such as Optum, commercial/BCBS dominance, and pharmacy benefit management. Concentration Risk in a Maturing Market: Medicare Advantage now covers over 50% of eligible seniors, transitioning from a high-growth secular trend to a mature, margin-compressed market. Humana’s outsized exposure to MA makes it highly sensitive to CMS rate notices, the v28 risk model phase-in, and regulatory scrutiny. While peers can cross-subsidize MA margin pressure with commercial or health services revenue, Humana’s earnings are inextricably linked to MA policy. The CenterWell Hedge: Humana’s primary defense for long-term market share stability is its vertical integration through CenterWell. The segment remains in high-growth mode, adding 100,600 patients (a >25% expansion) in 2025. Crucially, 68% of Humana’s individual MA members are now in value-based care (VBC) arrangements. This integrated delivery model is vital for managing the acuity of the incoming 2026 membership cohort and controlling specialty pharmacy costs. Medicaid Diversification: Humana has expanded its Medicaid footprint to 13 states, providing some top-line diversification. However, this segment carries structurally lower margins than optimized individual MA, meaning it dilutes overall enterprise margins during the MA turnaround phase. Key Risks & Uncertainties Execution Risk on Acuity Capture: The profitability of the 2026 membership surge depends entirely on Humana's ability to rapidly document patient acuity and route new members into CenterWell’s value-based clinics. Star Ratings Recovery Timeline: The $9.00 Adjusted EPS floor for 2026 assumes the Star Ratings drop is a one-year trough. Any failure to restore 4-star+ ratings for Bonus Year 2027 would structurally impair the long-term earnings recovery trajectory. Medical Cost Inflation: Persistent utilization pressures, particularly in outpatient services and specialty pharmacy, remain a systemic risk across the managed care sector.

Humana Inc. (HUM) Stock Price & AI Analysis

GoAI Score

Sign in to unlock

Valuation

50Fair Value

Sentiment

51Neutral

Risk

100Low Risk

Momentum

38Negative

Institutional-Grade Intelligence

🏆PRO

Actionable Intelligence

AI-driven stance, execution logic & risk thresholds

Catalyst Roadmap

Event timeline with expected impact & market context

Deep Insights

Fact-checked analysis & score logic breakdown

Financial Statements

Margin Trends

Gross

14.5%▼0.0pp

Revenue after COGS

Operating

1.1%▼0.3pp

After operating expenses

Net

0.9%▼0.1pp

Bottom-line profitability

Gross Margin

Operating Margin

Net Margin

Valuation Snapshot

P/E Ratio

26.0

Price vs earnings

EV/EBITDA

13.6

Enterprise value

FCF Yield

1.2%

Cash generation

Earnings Yield

3.9%

Inverse of P/E

Capital Efficiency

4

GoAI Quality ScoreWeak

ROEReturn on Equity

6.7%Fair

ROAReturn on Assets

2.4%Fair

ROICReturn on Invested Capital

3.1%Fair

Financial Health

Current RatioWeak

0.72

Short-term solvency (>1.5)

Net Debt / EBITDAHigh

3.00x

Debt repayment capacity (<3x)

Income QualityFair

0.78

Cash backs earnings (>1)

Revenue & Profitability

Revenue

Net Income

Net Loss

Income Statement

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$129.66B	$117.81B	$106.44B	$92.92B	$83.65B
Gross Profit	$18.85B	$17.15B	$18.05B	$17.23B	$14.45B
Gross Margin	14.5%	14.6%	17.0%	18.5%	17.3%
Operating Income	$1.45B	$1.63B	$3.32B	$3.56B	$3.42B
Net Income	$1.19B	$1.21B	$2.49B	$2.81B	$2.93B
Net Margin	0.9%	1.0%	2.3%	3.0%	3.5%
EPS	$9.87	$10.01	$20.09	$22.20	$22.79

Average Price Target

$235.00▲ 18.4% Upside

Past 12 Months

12 Month Forecast

Based on 50 Wall Street analysts offering 12 month price targets for Humana Inc., the average price target is $235.00, with a high forecast of $345.00 and a low forecast of $146.00. The average price target represents a 18.4% increase from the current price of $198.54.

Highest

$345.00

Average

$235.00

Lowest

$146.00

Rating Distribution

Strong Buy

0

0%

Buy

14

33%

Hold

27

63%

Sell

2

5%

Strong Sell

0

0%

Recent Analyst Ratings

FirmActionRatingDate

Barclays● Maintain

Equal Weight

2026-02-25

Wells Fargo● Maintain

Equal Weight

2026-02-18

Goldman Sachs● Maintain

Sell

2026-02-17

Truist Securities● Maintain

Hold

2026-02-17

TD Cowen● Maintain

Hold

2026-02-13

Cantor Fitzgerald● Maintain

Neutral

2026-02-12

UBS● Maintain

Neutral

2026-02-12

Jefferies● Maintain

Buy

2026-02-12

Guggenheim● Maintain

Buy

2026-02-12

RBC Capital▼ Downgrade

Outperform→Sector Perform

2026-02-12

Earnings History & Surprises

BEAT RATE

94%

Last 18 quarters

AVG SURPRISE

+5.9%

EPS vs Estimate

BEATS / MISSES

17/1

Last 18 quarters

LATEST EPS

$-3.96

Q1 '26

QUARTERLY EPS TREND

Estimated

Beat

Miss

QUARTERLY DETAIL

Q1 '26

+1.0%

$-3.96 vs $-4.00

Q4 '25

+10.6%

$3.24 vs $2.93

Q3 '25

+5.9%

$6.27 vs $5.92

Q2 '25

+15.0%

$11.58 vs $10.07

Q1 '25

+3.1%

$-2.16 vs $-2.23

Q4 '24

+22.4%

$4.16 vs $3.40

Q3 '24

+19.0%

$6.96 vs $5.85

Q2 '24

+18.1%

$7.23 vs $6.12

Q1 '24

-57.1%

$-0.11 vs $-0.07

Q4 '23

+8.7%

$7.78 vs $7.16

Q3 '23

+1.4%

$8.94 vs $8.82

Q2 '23

+1.2%

$9.38 vs $9.27

Investor Q&A

Top questions investors are asking about Humana Inc.

2 Questions

Ask GoAI anything about Humana Inc.

Latest News

No news available